The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2024
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kamenskikh E.M.

Siberian State Medical University

Alifirova V.M.

Siberian State Medical University

Pashkovskaya D.V.

Siberian State Medical University

Titova M.A.

Siberian State Medical University

Koroleva E.S.

Siberian State Medical University

Levchuk L.A.

Mental Health Research Institute — Tomsk National Research Medical Center Russian Academy of Sciences

Ivanova S.A.

Siberian State Medical University;
Mental Health Research Institute — Tomsk National Research Medical Center Russian Academy of Sciences

Serum neurofilament light chains in assessing the course of multiple sclerosis

Authors:

Kamenskikh E.M., Alifirova V.M., Pashkovskaya D.V., Titova M.A., Koroleva E.S., Levchuk L.A., Ivanova S.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(1): 89‑93

DOI: 10.17116/jnevro202412401189

Views: 743

Downloaded: 3

Buy for 200₽
Contact the author
Table of contents

To cite this article:

Kamenskikh EM, Alifirova VM, Pashkovskaya DV, Titova MA, Koroleva ES, Levchuk LA, Ivanova SA. Serum neurofilament light chains in assessing the course of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(1):89‑93. (In Russ.)
https://doi.org/10.17116/jnevro202412401189

Подписка 2025 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Biomarkers of neuroinflammation in patients with chro­nic cere­bral ischemia during the therapy with vinpocetine (study INFLAMARK). S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(12):50-58
Biochemical markers of autism. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(1):55-59
Plasma and sali­vary acetylcholinesterase acti­vity in amyotrophic late­ral scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(1):128-134
Prognostic significance of atrial natriuretic peptide in patients unde­rgoing cardiac surgery. Russian Journal of Anesthesiology and Reanimatology. 2023;(6):36-42
Mole­cular biomarkers in prediction of neurological outcomes after sudden cardiac arrest. Russian Journal of Anesthesiology and Reanimatology. 2023;(6):99-107
Allo­static load in patients with diabetic reti­nopathy. Russian Annals of Ophthalmology. 2023;(6):7-12
Analytical review of respiratory infe­ctions role in patients with chro­nic obstructive pulmonary disease and asthma. Part 1. Characteristics of respiratory infe­ctions and their long-term consequences. Russian Journal of Preventive Medi­cine. 2024;(1):90-96
Limi­tations and possibilities of treatment of patients with infe­rtility against the background of multiple scle­rosis disease during the COVID-19 pandemic. Russian Bulletin of Obstetrician-Gynecologist. 2024;(1):83-87
Labo­ratory diagnosis of neurosyphilis: opti­mization ways. Part II. Current approaches and biomarkers. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(1):28-36

OBJECTIVE

To study a role of serum neurofilament light chains (sNFL) in assessment of course and progression of multiple sclerosis (MS) in the population of patients with MS in the Tomsk region.

MATERIAL AND METHODS

The study involved 93 patients with relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) (nRRMS=75, nSPMS=18). The study was carried out in a two-stage design: the first stage was a cross-sectional study for the entire sample; the second stage was a prospective observation with two visits for patients with relapse. sNFL concentration was determined by solid-phase ELISA.

RESULTS

There was no statistically significant difference between RRMS and SPMS, and relapse and remission groups in terms of sNFL levels. Patients with a MS duration exceeding 14 years had higher rates of sNFL than those with a shorter duration (p=0.02). The subjects of the second study stage showed a decrease in sNFL from 2.05 (1.86; 2.19) pg/ml to 1.92 (1.87; 2.04) pg/ml (p=0.005), and slowdown in sNFL reduction correlated with the severity of cognitive impairment (k=0.52; p<0.05).

CONCLUSION

Dynamic monitoring of sNFL allows the evaluation of the activity of the disease, as well as making an assumption about the compensatory possibilities of subsequent recovery.

Keywords:

multiple sclerosis
biomarkers
neurofilaments
prognosis
progression

Authors:

Kamenskikh E.M.

Siberian State Medical University

Alifirova V.M.

Siberian State Medical University

Pashkovskaya D.V.

Siberian State Medical University

Titova M.A.

Siberian State Medical University

Koroleva E.S.

Siberian State Medical University

Levchuk L.A.

Mental Health Research Institute — Tomsk National Research Medical Center Russian Academy of Sciences

Ivanova S.A.

Siberian State Medical University;
Mental Health Research Institute — Tomsk National Research Medical Center Russian Academy of Sciences

Received:

21.07.2023

Accepted:

19.09.2023

List of references:

  1. Teunissen CE, Iacobaeus E, Khademi M. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009;72(15):1322-1329. https://doi.org/10.1212/WNL.0b013e3181a0fe3f
  2. Gunnarsson M, Malmeström C, Axelsson M. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011;69(1):83-89.  https://doi.org/10.1002/ana.22247
  3. Håkansson I, Tisell A, Cassel P. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Eur J Neurol. 2017;24(5):703-712.  https://doi.org/10.1111/ene.13274
  4. Novakova L, Axelsson M, Khademi M. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem. 2017;141(2):296-304.  https://doi.org/10.1111/jnc.13881
  5. Barro C, Benkert P, Disanto G. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain. 2018;141(8):2382-2391. https://doi.org/10.1093/brain/awy154
  6. Ulndreaj A, Sohaei D, Thebault S. Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay. Diagnosis (Berl). 2023;10(3):275-280.  https://doi.org/10.1515/dx-2022-0125
  7. Thebault S, Reaume M, Marrie RA. High or increasing serum NfL is predictive of impending multiple sclerosis relapses. Mult Scler Relat Disord. 2022;59:103535. https://doi.org/10.1016/j.msard.2022.103535
  8. Hradilek P, Revendova KZ, Horakova J. Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis. Biomed Pap Med Fac Univ Palacky Olomouc Czechoslov. 2023;167(1):30-35.  https://doi.org/10.5507/bp.2023.002
  9. Gisslén M, Price RW, Andreasson U. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine. 2015;3:135-140.  https://doi.org/10.1016/j.ebiom.2015.11.036
  10. Kuhle J, Barro C, Andreasson U. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med CCLM. 2016;54(10):1655-1661. https://doi.org/10.1515/cclm-2015-1195
  11. Rissin DM, Kan CW, Campbell TG. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28(6):595-599.  https://doi.org/10.1038/nbt.1641
  12. Kiseleva EV, Spirina NN, Spirin NN. Neurofilaments of light chains as a possible marker of the activity of the demilenizing process in multiple sclerosis. Materials of the 4th all-Russian congress with international participation «Multiple sclerosis and other demyelination diseases» (Nizhny Novgorod 24—26 sept. 2020). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(7-2):107-166. (In Russ.). https://doi.org/10.17116/jnevro2020120072107
  13. Thompson AJ, Banwell BL, Barkhof F. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173.  https://doi.org/10.1016/S1474-4422(17)30470-2
  14. Williams T, Tur C, Eshaghi A. Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial. Mult Scler Houndmills Basingstoke Engl. 2022;28(12):1913-1926. https://doi.org/10.1177/13524585221114441
  15. Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577-589.  https://doi.org/10.1038/s41582-018-0058-z
  16. Gordon BA. Neurofilaments in disease: what do we know? Curr Opin Neurobiol. 2020;61:105-115.  https://doi.org/10.1016/j.conb.2020.02.001

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.